These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 25637792)

  • 21. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
    Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
    Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
    Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
    J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignancy in chronic pancreatitis: analysis of diagnostic procedures and proposal of a clinical algorithm.
    Rückert F; Brussig T; Kuhn M; Kersting S; Bunk A; Hunger M; Saeger HD; Niedergethmann M; Post S; Grützmann R
    Pancreatology; 2013; 13(3):243-9. PubMed ID: 23719595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer.
    Felix K; Hinz U; Dobiasch S; Hackert T; Bergmann F; Neumüller M; Gronowitz S; Bergqvist M; Strobel O
    Pancreas; 2018 Jan; 47(1):72-79. PubMed ID: 29189449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
    Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
    Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Diagnosis of Autoimmune Pancreatitis From Pancreatic Cancer by Analysis of Serum Gelatinase Levels.
    Felix K; Dobiasch S; Gaida MM; Schneider K; Werner J; Martens E; Vandooren J; Opdenakker G
    Pancreas; 2016 Aug; 45(7):1048-55. PubMed ID: 26692441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
    Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
    World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study.
    Kimura H; Ohtsuka T; Matsunaga T; Watanabe Y; Tamura K; Ideno N; Aso T; Miyazaki T; Osoegawa T; Aishima S; Miyasaka Y; Ueda J; Ushijima Y; Igarashi H; Ito T; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Oct; 44(7):1148-54. PubMed ID: 26284536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
    Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
    LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
    Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
    PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling.
    Hocker JR; Lerner MR; Mitchell SL; Lightfoot SA; Lander TJ; Quillet AA; Hanas RJ; Peyton MD; Postier RG; Brackett DJ; Hanas JS
    Cancer Invest; 2011 Feb; 29(2):173-9. PubMed ID: 21261478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.